Jpmorgan Chase & CO Keros Therapeutics, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.27 Trillion
  • Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 2,600,457 shares of KROS stock, worth $36.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,600,457
Previous 213,431 1118.41%
Holding current value
$36.8 Million
Previous $3.38 Million 684.43%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025
BUY
$10.15 - $16.1 $24.2 Million - $38.4 Million
2,387,026 Added 1118.41%
2,600,457 $26.5 Million
Q4 2024

Feb 12, 2025
BUY
$15.64 - $70.0 $2.85 Million - $12.8 Million
182,314 Added 585.9%
213,431 $3.38 Million
Q3 2024

Dec 26, 2024
BUY
$41.68 - $58.07 $17,588 - $24,505
422 Added 1.37%
31,117 $1.81 Million
Q3 2024

Nov 08, 2024
BUY
$41.68 - $58.07 $17,588 - $24,505
422 Added 1.37%
31,117 $1.81 Million
Q2 2024

Dec 26, 2024
SELL
$44.58 - $66.89 $18,812 - $28,227
-422 Reduced 1.36%
30,695 $1.4 Million
Q2 2024

Aug 12, 2024
SELL
$44.58 - $66.89 $1.1 Million - $1.65 Million
-24,715 Reduced 44.6%
30,695 $1.4 Million
Q1 2024

Dec 26, 2024
BUY
$41.26 - $70.48 $1 Million - $1.71 Million
24,293 Added 78.07%
55,410 $3.67 Million
Q1 2024

May 10, 2024
SELL
$41.26 - $70.48 $298,474 - $509,852
-7,234 Reduced 11.55%
55,410 $3.67 Million
Q4 2023

Dec 26, 2024
BUY
$27.12 - $41.05 $855,012 - $1.29 Million
31,527 Added 101.32%
62,644 $2.49 Million
Q4 2023

Feb 12, 2024
BUY
$27.12 - $41.05 $259,674 - $393,053
9,575 Added 18.04%
62,644 $2.49 Million
Q3 2023

Nov 14, 2023
BUY
$31.57 - $43.02 $738,075 - $1.01 Million
23,379 Added 78.74%
53,069 $1.69 Million
Q2 2023

Aug 11, 2023
BUY
$37.26 - $51.01 $233,620 - $319,832
6,270 Added 26.77%
29,690 $1.19 Million
Q1 2023

May 18, 2023
BUY
$41.44 - $59.32 $962,941 - $1.38 Million
23,237 Added 12697.81%
23,420 $1 Million
Q1 2023

May 11, 2023
SELL
$41.44 - $59.32 $1.71 Million - $2.45 Million
-41,298 Reduced 99.56%
183 $7,000
Q4 2022

Feb 13, 2023
BUY
$39.45 - $51.77 $935,359 - $1.23 Million
23,710 Added 133.42%
41,481 $1.99 Million
Q3 2022

Nov 14, 2022
BUY
$27.8 - $40.12 $70,806 - $102,185
2,547 Added 16.73%
17,771 $669,000
Q2 2022

Aug 11, 2022
SELL
$26.03 - $67.04 $580,573 - $1.5 Million
-22,304 Reduced 59.43%
15,224 $420,000
Q1 2022

May 11, 2022
BUY
$42.12 - $59.36 $182,337 - $256,969
4,329 Added 13.04%
37,528 $2.04 Million
Q4 2021

Feb 10, 2022
BUY
$36.95 - $62.89 $838,654 - $1.43 Million
22,697 Added 216.12%
33,199 $1.94 Million
Q3 2021

Nov 12, 2021
BUY
$29.27 - $43.71 $307,393 - $459,042
10,502 New
10,502 $415,000

Others Institutions Holding KROS

# of Institutions
178
Shares Held
36.4M
Call Options Held
938K
Put Options Held
1.39M
View Full List

About Keros Therapeutics, Inc.

KROS Quotes by TradingView
  • Ticker KROS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,757,000
  • Market Cap $364M
  • Description
  • Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...
More about KROS
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email